FDC Beheer

Beheer criteriumcontroles 3/4

De CEO FDC is Nandan Chandavarkar, benoemd in Mar2004, heeft een ambtstermijn van 20.67 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 30.10M, bestaande uit 40.6% salaris en 59.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.1% van de aandelen van het bedrijf, ter waarde ₹ 2.44B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 11.3 jaar en 9.5 jaar.

Belangrijke informatie

Nandan Chandavarkar

Algemeen directeur

₹30.1m

Totale compensatie

Percentage CEO-salaris	40.6%
Dienstverband CEO	20.7yrs
Eigendom CEO	3.1%
Management gemiddelde ambtstermijn	11.3yrs
Gemiddelde ambtstermijn bestuur	9.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Nandan Chandavarkar's beloning veranderd ten opzichte van FDC's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	₹3b
Jun 30 2024	n/a	n/a	₹3b
Mar 31 2024	₹30m	₹12m	₹3b
Dec 31 2023	n/a	n/a	₹3b
Sep 30 2023	n/a	n/a	₹3b
Jun 30 2023	n/a	n/a	₹2b
Mar 31 2023	₹24m	₹10m	₹2b
Dec 31 2022	n/a	n/a	₹2b
Sep 30 2022	n/a	n/a	₹2b
Jun 30 2022	n/a	n/a	₹2b
Mar 31 2022	₹24m	₹11m	₹2b
Dec 31 2021	n/a	n/a	₹3b
Sep 30 2021	n/a	n/a	₹3b
Jun 30 2021	n/a	n/a	₹3b
Mar 31 2021	₹26m	₹10m	₹3b
Dec 31 2020	n/a	n/a	₹3b
Sep 30 2020	n/a	n/a	₹3b
Jun 30 2020	n/a	n/a	₹3b
Mar 31 2020	₹27m	₹9m	₹2b
Dec 31 2019	n/a	n/a	₹2b
Sep 30 2019	n/a	n/a	₹2b
Jun 30 2019	n/a	n/a	₹2b
Mar 31 2019	₹17m	₹7m	₹2b
Mar 31 2018	₹18m	₹7m	₹2b

Compensatie versus markt: De totale vergoeding ($USD 356.27K ) Nandan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 355.52K ).

Compensatie versus inkomsten: De vergoeding van Nandan is het afgelopen jaar met meer dan 20% gestegen.

CEO

Nandan Chandavarkar

20.7yrs

Tenure

₹30,103,131

Compensatie

Dr. Nandan Mohan Chandavarkar has been Joint Managing Director of FDC Limited since March 1, 2004 and serves as its Executive Director since September 30, 1993. Dr. Chandavarkar has been a Director at FDC...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Nandan Chandavarkar	Joint MD & Executive Director	20.7yrs	₹30.10m	3.1% ₹ 2.4b
Mohan Chandavarkar	BR Head	20.6yrs	₹38.71m	21.82% ₹ 17.2b
Ameya Chandavarkar	CEO of International Business & Executive Director	22.6yrs	₹20.20m	6.1% ₹ 4.8b
Ashok Chandavarkar	Whole Time Director	no data	₹20.60m	0.68% ₹ 538.5m
Vijay Bhatt	Chief Financial Officer	1.6yrs	geen gegevens	geen gegevens
Lalit Aggarwal	President of Technical & Operations	2yrs	geen gegevens	geen gegevens
Sanjay Jain	Vice President of Corporate Finance	1.6yrs	₹10.28m	geen gegevens
Varsharani Katre	Compliance Officer & Company Secretary	no data	₹4.01m	geen gegevens
Shashank Vyapari	Associate Vice President of Technical & Operations	no data	geen gegevens	geen gegevens
Anant Kharche	Associate Vice President of Engineering Services & Projects	no data	geen gegevens	geen gegevens

11.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van 531599 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 11.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Nandan Chandavarkar	Joint MD & Executive Director	31.2yrs	₹30.10m	3.1% ₹ 2.4b
Mohan Chandavarkar	BR Head	15.6yrs	₹38.71m	21.82% ₹ 17.2b
Ameya Chandavarkar	CEO of International Business & Executive Director	22.6yrs	₹20.20m	6.1% ₹ 4.8b
Ashok Chandavarkar	Whole Time Director	15yrs	₹20.60m	0.68% ₹ 538.5m
Nomita Chandavarkar	Non-Executive & Non-Independent Director	10.4yrs	₹600.00k	22.67% ₹ 17.9b
Uday Gurkar	Non-Executive Independent Chairman of the Board	8.6yrs	₹850.00k	geen gegevens
Mahesh Bijlani	Non-Executive & Independent Director	5.5yrs	₹600.00k	geen gegevens
Vijay Bhatt	Non-Executive & Independent Director	1.5yrs	₹600.00k	geen gegevens
Vijay Maniar	Non-Executive Independent Director	2.3yrs	₹850.00k	geen gegevens
Charuta Mandke	Non Executive Independent Director	less than a year	geen gegevens	geen gegevens

9.5yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 531599 wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.5 jaar).

FDC Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

FDC Limited Announces Cessation of CA Swati Sandesh Mayekar as Non-Independent Director

FDC Limited, Annual General Meeting, Sep 26, 2024

FDC Limited Announces Board Completion of Tenure of Independent Directors

FDC Limited, Annual General Meeting, Sep 27, 2023

FDC Limited Approves Appointment of Vijay S. Maniar as an Non-Executive and Independent Director

Board Member recently bought ₹912k worth of stock

Recent updates

Upcoming dividend of ₹5.00 per share

Second quarter 2025 earnings released: EPS: ₹4.43 (vs ₹4.22 in 2Q 2024)

FDC Limited to Report Q2, 2025 Results on Nov 06, 2024

FDC Limited Announces Cessation of CA Swati Sandesh Mayekar as Non-Independent Director

FDC Limited, Annual General Meeting, Sep 26, 2024

First quarter 2025 earnings released: EPS: ₹7.31 (vs ₹6.62 in 1Q 2024)

FDC Limited to Report Q1, 2025 Results on Aug 07, 2024

Full year 2024 earnings released: EPS: ₹18.58 (vs ₹11.67 in FY 2023)

FDC Limited Announces Board Completion of Tenure of Independent Directors

Third quarter 2024 earnings released: EPS: ₹4.86 (vs ₹2.45 in 3Q 2023)

Second quarter 2024 earnings released: EPS: ₹4.22 (vs ₹3.10 in 2Q 2023)

FDC Limited to Report Fiscal Year 2024 Results on May 29, 2024

FDC Limited, Annual General Meeting, Sep 27, 2023

FDC Limited (BSE:531599) agreed to acquire remaining 7% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd. from other existing shareholders.

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: EPS: ₹6.62 (vs ₹4.23 in 1Q 2023)

FDC Limited to Report Q1, 2024 Results on Aug 09, 2023

Full year 2023 earnings released: EPS: ₹11.66 (vs ₹12.82 in FY 2022)

Full year 2023 earnings released: EPS: ₹11.66 (vs ₹12.82 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹2.45 (vs ₹2.11 in 3Q 2022)

FDC Limited to Report Q3, 2023 Results on Feb 09, 2023

Second quarter 2023 earnings released: EPS: ₹3.10 (vs ₹4.28 in 2Q 2022)

Price target increased to ₹375

FDC Limited Approves Appointment of Vijay S. Maniar as an Non-Executive and Independent Director

FDC Limited to Report Q4, 2023 Results on May 23, 2023

First quarter 2023 earnings released: EPS: ₹4.23 (vs ₹5.80 in 1Q 2022)

FDC Limited to Report Q1, 2023 Results on Aug 04, 2022

Board Member recently bought ₹912k worth of stock

Insufficient new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

FDC Limited to Report Q4, 2022 Results on May 25, 2022

Price target decreased to ₹415

Fdc Limited Announces That Nomita R. Chandavarkar Has Stepped Down from the Position of the Executive Director of the Company to Non-Executive Director with Effect from April 01, 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

FDC Limited (BSE:531599) announces an Equity Buyback for 2,900,000 shares, representing 1.72% for INR 1,377.5 million.

Second quarter 2022 earnings released: EPS ₹4.28 (vs ₹5.15 in 2Q 2021)

Price target decreased to ₹415

First quarter 2022 earnings released: EPS ₹5.80 (vs ₹5.36 in 1Q 2021)

FDC Limited Launches Favipiravir Oral Suspension -Favenza

Full year 2021 earnings released: EPS ₹17.72 (vs ₹13.94 in FY 2020)

Price target raised to ₹470

New 90-day low: ₹280

Third quarter 2021 earnings released: EPS ₹4.47 (vs ₹4.31 in 3Q 2020)

FDC Limited to Report Q3, 2021 Results on Feb 04, 2021

New 90-day low: ₹311

Second quarter 2021 earnings released: EPS ₹5.15

Revenue and earnings beat expectations

New 90-day high: ₹368

New 90-day high - ₹349

FDC Limited to Report Q1, 2021 Results on Aug 07, 2020

FDC Limited (BSE:531599) entered into definitive agreements to acquire an additional 44% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd from Pharma-Q Holdings Pty for ZAR 0.14 million.

First quarter earnings released

FDC Limited (BSE:531599) entered into definitive agreements to acquire an additional 44% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd from Pharma-Q Holdings Pty for ZAR 0.14 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd